COMPANY PROFILE

Biond Biologics

Explore full profile

Innovative immunotherapies and a pioneering intracellular delivery for biologics for the treatment of patients

Misgav Am, IsraelFounded 2016Biotech & Life Sciences

Valuation $50–100M Last recorded · 2026

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Biond Biologics

Biond Biologics is a biotechnology company focused on developing innovative therapies for novel oncology targets. The company operates in the biopharmaceutical market, aiming to uncover immunoregulatory pathways and enable the intracellular delivery of biologics. Biond Biologics serves clients in the pharmaceutical and healthcare sectors, including global pharma companies through collaborations and partnerships. The business model revolves around research and development (R&D) of proprietary technology platforms and novel therapeutic agents, such as BND-22, a macrophage activator currently in IND-enabling studies. The company generates revenue through strategic partnerships, licensing agreements, and financing rounds, including a completed Series B financing with participation from global biopharma companies. Biond Biologics has established a sustainable R&D hub in the Galilee, Israel, and continues to advance its pipeline of oncology therapies through rigorous proof-of-concept studies and clinical trials.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Misgav Am, Israel
Employees: 35
Open positions: None listed
Dealroom signal: 30.9/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Developer Tools, Biotechnology, Oncology, Autoimmune, Immune System, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VC✓Equity / VC	Jun 2026	$8M	$85M	Guangzhou Industrial Investment Fund	↗
SERIES C✓Equity / VC	Nov 2021	$15M	$85M	Heritage Group · Deep Insight · Harel Group	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Biond Biologics website traffic

Latest recorded traffic for Biond Biologics is 320 monthly website visits, up 255.6% over the last three months. Biond Biologics's team declined 2.8% over the past year.

Latest monthly visits320 3-month web change+255.6% 1-year team growth-2.8%

Monthly website visitsOct 2017–Mar 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CPCorvus PharmaceuticalsClinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer	Burlingame, United States	Operational	53	$109M	$1B
ABAdicet BioA biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR t cell therapies for cancer	Redwood City, United States	Operational
ATAvila TherapeuticsFocused on the development of covalent drugs to treat cancer and other autoimmune diseases	Waltham, United States	Acquired
TBThemis BioscienceDeveloping vaccines to prevent infectious diseases	Vienna, Austria	Acquired
ETEureka TherapeuticsBiotechnology company focuses on an immunotherapies for the treatment of cancer	Emeryville, United States	Operational
KMKAHR MedicalDeveloping an innovative and novel drug platform of immunotherapeutic bi-functional fusion proteins that harness the human immune system to target multiple cancer indications	Jerusalem, Israel	Operational
EVEvelo Biosciences (Formerly Evelo Therapeutics, VL28)Development of monoclonal microbials	Cambridge, United States	Operational
OROrgenesisDeveloping and manufacturing cell-therapy solutions	Tel Aviv-Yafo, Israel	Operational